Fulcrum Therapeutics, Inc.
NASDAQ:FULCBiotechnology
+$0.06 today
- Market cap
- $284.14M
- Beta
- 2.92
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.00
Volume 0.63M
Average 1.78M
FULC Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Fulcrum Therapeutics, Inc.NASDAQ: FULC
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures turns negative
Q1 FY2026 capital expenditures was -$8K, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$322K. Over 3 fiscal years it compounded at -45.7% a year.
Context
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near -$8K or moves back toward the trailing-twelve-month quarterly average of -$80.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (314K) USD
- Year-over-year change
- -12.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (314K) | -12.9% |
| FY2024 | 2024-12-31 | (278K) | +45.3% |
| FY2023 | 2023-12-31 | (508K) | +74.1% |
| FY2022 | 2022-12-31 | (1.96M) | -14.6% |
| FY2021 | 2021-12-31 | (1.71M) | — |
Capital Expenditures vs competitors
How FULC compares with its peers on the latest reported figures
- FULC's LTM Mar 2026 capital expenditures of $322K is the 2nd largest of the 10 companies compared; the peer median is $89K.
- Its year-over-year change of +28.8% is the 3rd highest of 9, against a peer median of -69.7%.
- Over three fiscal years its annual growth of -45.7% compares with a peer median of -27.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $669.4K | -56.0% | -19.0% | — | |
| LTM Mar 2026 | $322K | +28.8% | -45.7% | — | |
| LTM Mar 2026 | $192K | -54.7% | +8.1% | 1.3% | |
| LTM Mar 2026 | $175K | -83.3% | -65.4% | 3.9% | |
| LTM Mar 2026 | $106.68K | -94.2% | -50.1% | 0.2% | |
| LTM Mar 2026 | $89K | +43.5% | -51.0% | — | |
| LTM Mar 2026 | $57.04K | -90.5% | -27.3% | 0.1% | |
| LTM Mar 2026 | $24K | -83.8% | -16.8% | 0.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $16K | — | — | — |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Peer median (excluding FULC) | $89K | -69.7% | -27.3% | 0.2% | |
Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (80.85M) | (109.87M) | (97.34M) | (9.73M) | (74.88M) |
| Depreciation & Amortization | 2.52M | 2.41M | 2.17M | 1.59M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.07M | 13.35M | 14.8M | 14.55M | 12.47M |
| Change in Working Capital | (11.89M) | (3.09M) | (4.61M) | (4.25M) | 3.91M |
| Accounts Receivables | (500K) | 2.5M | (308K) | (1.56M) | 2.1M |
| Inventory | 1.25M | 0 | 0 | 0 | 0 |
| Accounts Payables | 973K | (1.18M) | (853K) | (1.59M) | 428K |
| Other Working Capital | (13.61M) | (4.42M) | (3.45M) | (1.1M) | 1.39M |
| Other Non-Cash Items | 673K | 152K | (5.99M) | (4.39M) | (2.95M) |
| Operating Cash Flow | (78.48M) | (97.05M) | (90.97M) | (2.22M) | (60.07M) |
| Capital Expenditures | (1.71M) | (1.96M) | (508K) | (278K) | (314K) |
| Acquisitions (Net) | 127.96M | (14.38M) | 0 | 0 | 0 |
| Purchases of Investments | (216.23M) | (151.15M) | (194.89M) | (178.59M) | (180.22M) |
| Sales of Investments | 88.28M | 165.53M | 158.71M | 211.1M | 211.25M |
| Other Investing Activities | (127.96M) | 14.38M | 0 | 0 | 0 |
| Investing Cash Flow | (129.67M) | 12.41M | (36.69M) | 32.23M | 30.72M |
| Debt Repayment | (18K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 182.86M | 80.8M | 117.35M | 2.75M | 168.67M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.67M | 3.52M | 777K | 0 | 0 |
| Financing Cash Flow | 186.51M | 84.32M | 118.12M | 2.75M | 168.67M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (21.64M) | (314K) | (9.54M) | 32.76M | 139.32M |
| Free Cash Flow | (80.19M) | (99.01M) | (91.47M) | (2.5M) | (60.38M) |
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
Intrinsic Alpha fair value
Locked
Current Price
$3.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.